Trust in physicians and hospitals declined over the course of the COVID-19 pandemic
In surveys completed throughout the COVID-19 pandemic by U.S. adults, trust in physicians and hospitals decreased over time in every socioeconomic group.
NewsMay | 14 | 2020
As part of its COVID-19 response, the Ragon Institute of MGH, MIT and Harvard is working within the Massachusetts Consortium for Pathogen Readiness (MassCPR), a multi-institutional initiative convened by Harvard Medical School and the Ragon Institute, to combat the disease and prepare for future outbreaks.
The MassCPR recently announced the awarding of more than $16.5 million in funding to support 62 research projects that address the most pressing challenges of the pandemic. Six of the awards were given to Ragon Institute members with affiliations.
Ragon Institute director, Bruce Walker, MD, serves as co-director and founding member, and many of our members, steering committee members and group leaders are working within the MassCPR to combat COVID-19.
“I think most of us pursued careers in science hoping that we would someday have the opportunity to work on something that truly had meaning and that would allow us to work together in collaboration rather than competition,” said Walker. “I feel we have found that here in the MassCPR.”
Funding was provided by the China Evergrande Group and donations, including support of $1 million or more each from Mark and Lisa Schwartz, the MLSC and the Bertarelli Foundation.
“We’re thrilled to be supporting MassCPR in unraveling the mysteries of SARS CoV2. We believe we’re investing in the best doctors and scientists in the world, and we hope our financial support will help establish the best testing protocols, the most effective treatments and the safest vaccines,” says donors Mark and Lisa Schwartz.
The total list of projects can be found at https://masscpr.hms.harvard.edu/research.
We harness the immune system to prevent and cure human disease. Currently, we are using our resources and scientists to focus on SARS-CoV-2.
In surveys completed throughout the COVID-19 pandemic by U.S. adults, trust in physicians and hospitals decreased over time in every socioeconomic group.
BCG-treated individuals had a significantly lower rate of COVID-19 infection compared with the placebo group and a significantly lower rate of infectious diseases overall.
Researchers found that a person with a diagnosis of Down syndrome and COVID-19 pneumonia had six times the odds of having a Do Not Resuscitate (DNR) status ordered at hospital admission.
Aram J. Krauson, PhD, of the Department of Pathology at Mass General, is the first author and James Stone, MD, PhD, is the senior author of a new study in NPJ Vaccines, Duration of SARS-CoV-2 mRNA Vaccine Persistence and Factors Associated with Cardiac Involvement in Recently Vaccinated Patients.
Treatment improved blood oxygen levels and lowered the risk of long-term sensory and motor neurologic symptoms.
Results indicate a link between reduced mobility during the pandemic and greater risk for depressive symptoms.